Coexistence of tyrosine kinase inhibitor-sensitizing and resistant EGFR mutations in an untreated lung adenocarcinoma patient and response to erlotinib

Letter/Communication

Open access

Gagan Mathur and Deqin Ma

Journal of thoracic oncology, Vol.9(7), pp.e55-e57

07/2014

DOI: 10.1097/JTO.0000000000000197

PMID: 24926557

Files and links (1)

url

https://doi.org/10.1097/JTO.0000000000000197View

Published (Version of record) Open Access

Mutation

Palliative Care

Erlotinib Hydrochloride

Lung Neoplasms - genetics

Lung Neoplasms - drug therapy

Humans

Middle Aged

ErbB Receptors - genetics

Bone Neoplasms - secondary

Lung Neoplasms - pathology

Male

Antineoplastic Agents - therapeutic use

Adenocarcinoma - drug therapy

Adenocarcinoma - secondary

Bone Neoplasms - radiotherapy

Drug Resistance, Neoplasm - genetics

Protein Kinase Inhibitors - therapeutic use

Quinazolines - therapeutic use

Adenocarcinoma - genetics

Title: Subtitle: Coexistence of tyrosine kinase inhibitor-sensitizing and resistant EGFR mutations in an untreated lung adenocarcinoma patient and response to erlotinib
Creators: Gagan Mathur - Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA
Deqin Ma - Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA. Electronic address: deqin-ma@uiowa.edu
Resource Type: Letter/Communication
Publication Details: Journal of thoracic oncology, Vol.9(7), pp.e55-e57
Publisher: United States
DOI: 10.1097/JTO.0000000000000197
PMID: 24926557
ISSN: 1556-0864
eISSN: 1556-1380
Language: English
Date published: 07/2014
Academic Unit: Pathology
Record Identifier: 9984047734402771

17 Record Views